Lower limb high arterial flow induced by tenofovir and emtricitabine treatment.
نویسندگان
چکیده
Here, we describe a case of an HIV-infected patient with right lower limb oedema that appeared after initiation of tenofovir and emtricitabine treatment. The patient was fully investigated by serial heart and vessel echo-Doppler examination. Oedema of the lower limb was attributed to a transient drug-induced fivefold increase in peripheral artery flow, which was induced by a reduction in peripheral arterial resistance. The possible mechanisms of disease are discussed.
منابع مشابه
Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine
BACKGROUND Antiretroviral treatment (cART) in HIV causes lipoatrophy. We examined predictors of anthropometric outcomes over 96 weeks in HIV-infected, lipoatrophic adults receiving stable cART randomised to tenofovir-emtricitabine (TDF-FTC) or abacavir-lamivudine (ABC-3TC) fixed dose combinations. METHODOLOGY/PRINCIPAL FINDINGS The STEAL study was a prospective trial of virologically suppress...
متن کاملSimultaneous estimation of tenofovir disoproxil, emtricitabine and efavirenz in tablet dosage form by RP-HPLC
A simple, precise, rapid and accurate reverse phase HPLC method in isocratic mode has been developed for the estimation of Tenofovir disoproxil, Emtricitabine and Efavirenz in tablet dosage form. A Hypersil BDS C18, 250x4.6 mm, 5 μm partical size, with mobile phase consisting of acetonitrile and 0.03 M KH2PO4 water (pH adjusted to 3.2 with orthophosphoric acid) in the ratio of 60:40 v/v was use...
متن کاملBictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
BACKGROUND All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as components of initial HIV therapy. Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a 10 day monotherapy study and has a high in-vitro resistance barrier. On the basis of these results, we did a phase 2 trial comparing bictegravir with dolutegravir. METHODS In this...
متن کاملNew option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
Fixed-dose combination tablets have become an important therapy option for patients infected with the human immunodeficiency virus. Fixed-dose combination rilpivirine-tenofovir-emtricitabine is a recently approved therapy option that has been extensively studied within the treatment-naïve population. When compared with efavirenz-based therapy, improved tolerability with rilpivirine-based therap...
متن کاملAcute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
The fixed-dose combination of Efavirenz/Emtricitabine/Tenofovir is a first-line agent for the treatment of HIV; however few cases have reported hepatotoxicity associated with the drug. We report a case of Efavirenz/Emtricitabine/Tenofovir-associated hepatotoxicity presenting mainly with hepatocellular injury characterized by extremely elevated aminotransferase levels, which resolved without acu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Antiviral therapy
 
دوره 14 6 شماره
صفحات -
تاریخ انتشار 2009